Mark E. Flanagan

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball et al. · Science · 2003 · 670 citations · Full text

Medicine, Immunology, Pharmacology +17

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

Mark E. Flanagan, Todd A. Blumenkopf, William H. Brissette et al. · Journal of Medicinal Chemistry · 2010 · 335 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors

Mark E. Flanagan, J. A. Abramite, Dennis P. Anderson et al. · Journal of Medicinal Chemistry · 2014 · 324 citations

Pharmacy, Chemistry, Medicinal Chemistry +15

Identification of <i>N</i>-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases

Michael L. Vazquez, Neelu Kaila, Joseph W. Strohbach et al. · Journal of Medicinal Chemistry · 2018 · 171 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

DNA-encoded chemical libraries

Alexander L. Satz, Andreas Brunschweiger, Mark E. Flanagan et al. · Nature Reviews Methods Primers · 2022 · 169 citations